



**ANALGESIC, ANETHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES
AND NETWORKS
BEYOND THE MU OPIOID SYSTEM FOR TREATING OUD
NOVEMBER 21-22, 2019**

PARTICIPANT LIST

<p>Jane B. Acri, PhD Chief Medication Discovery and Toxicology Branch NIDA/NIH Bethesda, Maryland</p>	<p>Maryam Afshar, MD Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) Office of New Drugs, CDER, FDA Silver Spring, Maryland</p>
<p>Sarah Arnold, MD, MPH Medical Officer DAAAP Office of Drug Evaluation-II OND, CDER, FDA Silver Spring, Maryland</p>	<p>Rob Barrow, MS Director of Drug Development & Discovery Usona Institute Madison, Wisconsin</p>
<p>CAPT. Sean J. Belouin, PharmD Office of Medical Policy Center for Drug Evaluation & Research FDA Silver Spring, Maryland</p>	<p>Cecilia Bergeria, PhD Postdoctoral Research Fellow Behavioral Pharmacology Research Unit Johns Hopkins University School of Medicine Baltimore, Maryland</p>
<p>Michael Bogenschutz, MD Professor of Psychiatry NYU School of Medicine New York, New York</p>	<p>Katherine Bonson, PhD Pharmacologist Center for Drug Evaluation & Research FDA Silver Spring, Maryland</p>
<p>Randall Brown, MD, PhD, DFASAM Associate Professor University of Wisconsin School of Medicine and Public Health Madison, Wisconsin</p>	<p>Sandra D. Comer, PhD Professor of Neurobiology Columbia University and New York State Psychiatric Institute New York, New York</p>
<p>Emily Deng, MD, PhD Acting Pain Team Leader DAAAP, FDA Silver Spring, Maryland</p>	<p>Kelly Dunn, PhD Associate Professor Johns Hopkins University Baltimore, Maryland</p>
<p>Robert Dworkin, PhD Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry Director, ACTION, a public-private partnership with the FDA University of Rochester School of Medicine and Dentistry Rochester, New York</p>	<p>Patrick Finan, PhD Associate Professor Johns Hopkins University – Department of Psychiatry and Behavioral Sciences Baltimore, Maryland</p>

<p>Gioia M. Guerrieri, DO Medical Officer DAAAP, FDA Silver Spring, Maryland</p>	<p>Roland Griffiths, PhD Professor, Department of Psychiatry and Neuroscience Johns Hopkins University School of Medicine Baltimore, Maryland</p>
<p>Peter Hendricks, PhD Associate Professor University of Alabama at Birmingham School of Public Health Birmingham, Alabama</p>	<p>Els Houtsmuller, PhD Associate Director, Science Patient Centered Outcomes Research Institute Washington, DC</p>
<p>Andrew Huhn, PhD, MBA Assistant Professor Johns Hopkins University School of Medicine Baltimore, Maryland</p>	<p>Matthew W. Johnson, PhD Associate Professor of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore, Maryland</p>
<p>Kyle Kampman, MD Professor of Psychiatry Center for Studies of Addiction Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania</p>	<p>Brian Kiluk, PhD Associate Professor of Psychiatry Yale School of Medicine New Haven, Connecticut</p>
<p>Bethea (Annie) Kleykamp, MA, PhD Research Associate Professor Communications Director ACTION University of Rochester School of Medicine and Dentistry Rochester, New York</p>	<p>Thomas Kosten, MD Professor of Psychiatry Baylor College of Medicine Houston, Texas</p>
<p>Dustin C. Lee, PhD Assistant Professor of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore, Maryland</p>	<p>Frances R. Levin, MD Kennedy-Leavy Professor of Psychiatry New York State Psychiatric Institute Columbia University Irving Medical Center New York, New York</p>
<p>Allison Lin, PhD, PharmD Associate Director for Special Projects Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) FDA Silver Spring, Maryland</p>	<p>Naomi Lowy, MD Acting Deputy Director Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) FDA Silver Spring, Maryland</p>
<p>Aimee McRae-Clark, PharmD Professor of Psychiatry Medical University of South Carolina Ralph H. Johnson VA Medical Center Charleston, South Carolina</p>	<p>Javier A. Muniz, MD Associate Director Division of Psychiatry FDA Silver Spring, Maryland</p>

<p>Marco Pravetoni, PhD Associate Professor of Pharmacology and Medicine University of Minnesota Medical School Minneapolis, Minnesota</p>	<p>Kenzie L. Preston, PhD Chief, Clinical Pharmacology and Therapeutics Research Branch NIDA, NIH Bethesda, Maryland</p>
<p>Charles Raison, MD Professor University of Wisconsin Madison Usona Institute Madison, Wisconsin</p>	<p>Tanya Ramey, MD, PhD Medical Officer NIDA, NIH Bethesda, Maryland</p>
<p>Kurt Rasmussen, PhD Director, Division of Therapeutics and Medical Consequences NIDA, NIH Bethesda, Maryland</p>	<p>David Shurtleff, PhD Deputy Director, National Center for Complimentary and Integrative Health NIH Bethesda, Maryland</p>
<p>Eric Strain, MD Director, Center for Substance Abuse Treatment and Research Professor Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore, Maryland</p>	<p>Juliette Touré, PharmD, MBA CAPT, United States Public Health Service Senior Policy Advisor Division of Psychiatry Products Office of New Drugs-I, FDA Silver Spring, Maryland</p>
<p>Dennis Turk, PhD John and Emma Bonica Endowed Chair of Anesthesiology & Pain Medicine University of Washington School of Medicine Seattle, Washington</p>	<p>Ryan Vandrey, PhD Associate Professor Johns Hopkins University School of Medicine Baltimore, Maryland</p>
<p>Robert (Bob) Walsh, BS, RAC Regulatory Affairs Branch Division of Therapeutics and Medical Consequences NIDA, NIH Bethesda, Maryland</p>	<p>Kevin Walton, PhD Chief, Clinical Research Grants Branch NIDA, NIH Bethesda, Maryland</p>
<p>Roger Weiss, MD Professor of Psychiatry Harvard Medical School Chief, Division of Alcohol and Drug Abuse McLean Hospital Belmont, Massachusetts</p>	<p>Celia Winchell, MD Clinical Team Leader DAAAP, ODE-II FDA Silver Spring, Maryland</p>